Waldencast plc

NasdaqCM WALD

Waldencast plc EBITDA for the Trailing 12 Months (TTM) ending June 30, 2024: USD 97.37 M

Waldencast plc EBITDA is USD 97.37 M for the Trailing 12 Months (TTM) ending June 30, 2024, a 175.61% change year over year. EBITDA means earnings before interest, taxes, depreciation, and amortization, which measures a company's operating performance by excluding non-operating expenses.
  • Waldencast plc EBITDA for the Trailing 12 Months (TTM) ending June 30, 2023 was USD -128.77 M, a -1,688.35% change year over year.
  • Waldencast plc EBITDA for the Trailing 12 Months (TTM) ending July 27, 2022 was USD 8.11 M.
Key data
Date EBITDA Net Income EPS (Diluted) Shares (Diluted, Weighted)
Market news
Loading...
NasdaqCM: WALD

Waldencast plc

CEO Mr. Michel Brousset
IPO Date May 12, 2021
Location United States
Headquarters 10 Bank Street
Employees 284
Sector Consumer Discretionary
Industries
Description

Waldencast Acquisition Corp. a skin care company, provides advanced skin care treatments. Its products are designed to help minimize the appearance of premature skin aging, skin damage, hyperpigmentation, acne, and sun damage primarily available through dermatologists, plastic surgeons, medical spas, and other skin care professionals. Its portfolio includes Obagi Medical that provides transformational skin care products formulated to minimize signs of skin aging, address dark spots, hyperpigmentation, fine lines, and wrinkles and to protect and enhance skin tone and texture; and Obagi Clinical that offers skin care products designed to prevent the early signs of skin aging. The company was founded in 1988 and is based in White Plains, New York.

Similar companies

VERX

Vertex, Inc.

USD 52.91

0.92%

VTEX

VTEX

USD 5.95

2.23%

WFCF

Where Food Comes From, Inc.

USD 12.69

0.08%

StockViz Staff

January 15, 2025

Any question? Send us an email